Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer)

Several clinical trials have demonstrated the benefit of adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The comparison of outcomes between nonrandomized groups of patients who received similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcon, Silvia, Riva, Luis, Flores, Christina, Vera, Delphis, Pinto, Joseph A., Gomez, Henry L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848732/
https://www.ncbi.nlm.nih.gov/pubmed/35251621
http://dx.doi.org/10.3892/mco.2022.2503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8848732/
https://www.ncbi.nlm.nih.gov/pubmed/35251621
http://dx.doi.org/10.3892/mco.2022.2503

Ejemplares similares